Integration and acquisition costs	9 Months Ended
Sep. 30, 2014
IntegrationAndAcquisitionCosts[Abstract]
Integration and acquisition costs	5. Integration and acquisition costs For the three months to September 30, 2014 Shire recorded integration and acquisition costs of $37.1 million (2013: $18.4 million), which included a net charge of $4.9 million relating to changes in the fair values of contingent consideration liabilities. Integration and acquisition costs also included costs of $32.2 million primarily related to the acquisition and integration of ViroPharma in the three months to September 30, 2014. For the nine months to September 30, 2014 Shire recorded integration and acquisition costs of $155.8 million (2013: $39.9 million), comprising costs of $129.5 million primarily related to the acquisition and integration of ViroPharma and a net charge of $26.3 million relating to the change in fair values of contingent consideration liabilities. The change in fair value of contingent consideration liabilities in the nine months to September 30, 2014 principally relates to the acquisition of SARcode BioSciences Inc. (“SARcode”), reflecting Shire's increased confidence in the lifitegrast program and the acquisition of FerroKin BioSciences, Inc. (“FerroKin”), reflecting the decision to place the ongoing Phase 2 clinical trial for SHP602 on clinical hold. In the three and nine months to September 30, 2013 integration and acquisition costs primarily related to the acquisitions of SARcode and Lotus Tissue Repair Inc. (“Lotus Tissue Repair”) in addition to net charges related to the change in fair values of contingent consideration liabilities.

Integration and acquisition costs

9 Months Ended

Sep. 30, 2014

IntegrationAndAcquisitionCosts[Abstract]

5. Integration and acquisition costs

For the three months to September 30, 2014 Shire recorded integration and acquisition costs of $37.1 million (2013: $18.4 million), which included a net charge of $4.9 million relating to changes in the fair values of contingent consideration liabilities. Integration and acquisition costs also included costs of $32.2 million primarily related to the acquisition and integration of ViroPharma in the three months to September 30, 2014.

For the nine months to September 30, 2014 Shire recorded integration and acquisition costs of $155.8 million (2013: $39.9 million), comprising costs of $129.5 million primarily related to the acquisition and integration of ViroPharma and a net charge of $26.3 million relating to the change in fair values of contingent consideration liabilities. The change in fair value of contingent consideration liabilities in the nine months to September 30, 2014 principally relates to the acquisition of SARcode BioSciences Inc. (“SARcode”), reflecting Shire's increased confidence in the lifitegrast program and the acquisition of FerroKin BioSciences, Inc. (“FerroKin”), reflecting the decision to place the ongoing Phase 2 clinical trial for SHP602 on clinical hold.

In the three and nine months to September 30, 2013 integration and acquisition costs primarily related to the acquisitions of SARcode and Lotus Tissue Repair Inc. (“Lotus Tissue Repair”) in addition to net charges related to the change in fair values of contingent consideration liabilities.